Innocare Shares Surge Over 4% in Afternoon Trading Following Milestone in Novel Anti-Inflammatory Drug Trial

Stock News05-21

Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million.

The increase follows the company's announcement that the Phase 1 clinical trial for its novel, oral, potentially best-in-class IL-17AA/AF inhibitor, ICP-054 (also known as ZB021), has enrolled its first subject. Currently, there are no oral IL-17 inhibitors approved for market or in late-stage development globally. The oral small-molecule profile of ICP-054 has the potential to offer advantages in dosing convenience, patient adherence, and clinical accessibility over currently approved biologic IL-17 therapies.

Notably, in October 2025, the company's wholly-owned subsidiary, Innocare Pharma Inc., entered into a licensing agreement with Zenas BioPharma, Inc. Under this agreement, Innocare granted Zenas the exclusive rights to develop, manufacture, and commercialize the oral IL-17AA/AF inhibitor ICP-054 (ZB021) in all regions outside of Greater China and Southeast Asia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186054640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186054640","market":"fut","top_or_hot":-1,"title":"Innocare Shares Surge Over 4% in Afternoon Trading Following Milestone in Novel Anti-Inflammatory Drug Trial","media":"Stock News","content":"<p>Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million.</p>\n<p>The increase follows the company's announcement that the Phase 1 clinical trial for its novel, oral, potentially best-in-class IL-17AA/AF inhibitor, ICP-054 (also known as ZB021), has enrolled its first subject. Currently, there are no oral IL-17 inhibitors approved for market or in late-stage development globally. The oral small-molecule profile of ICP-054 has the potential to offer advantages in dosing convenience, patient adherence, and clinical accessibility over currently approved biologic IL-17 therapies.</p>\n<p>Notably, in October 2025, the company's wholly-owned subsidiary, Innocare Pharma Inc., entered into a licensing agreement with Zenas BioPharma, Inc. Under this agreement, Innocare granted Zenas the exclusive rights to develop, manufacture, and commercialize the oral IL-17AA/AF inhibitor ICP-054 (ZB021) in all regions outside of Greater China and Southeast Asia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocare Shares Surge Over 4% in Afternoon Trading Following Milestone in Novel Anti-Inflammatory Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocare Shares Surge Over 4% in Afternoon Trading Following Milestone in Novel Anti-Inflammatory Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 14:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million.</p>\n<p>The increase follows the company's announcement that the Phase 1 clinical trial for its novel, oral, potentially best-in-class IL-17AA/AF inhibitor, ICP-054 (also known as ZB021), has enrolled its first subject. Currently, there are no oral IL-17 inhibitors approved for market or in late-stage development globally. The oral small-molecule profile of ICP-054 has the potential to offer advantages in dosing convenience, patient adherence, and clinical accessibility over currently approved biologic IL-17 therapies.</p>\n<p>Notably, in October 2025, the company's wholly-owned subsidiary, Innocare Pharma Inc., entered into a licensing agreement with Zenas BioPharma, Inc. Under this agreement, Innocare granted Zenas the exclusive rights to develop, manufacture, and commercialize the oral IL-17AA/AF inhibitor ICP-054 (ZB021) in all regions outside of Greater China and Southeast Asia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1186054640","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186054640","pubTimestamp":1779343714,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million. The increase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","688428":"诺诚健华","BK0239":"医药制造","06978":"永泰生物-B","BK4588":"碎股","09969":"诺诚健华","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"新型抗炎药物试验取得里程碑后，诺诚健华股价在下午交易中飙升超过4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688428":1,"09969":1,"06978":1,"VXUS":1},"content_text":"Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million.\nThe increase follows the company's announcement that the Phase 1 clinical trial for its novel, oral, potentially best-in-class IL-17AA/AF inhibitor, ICP-054 (also known as ZB021), has enrolled its first subject. Currently, there are no oral IL-17 inhibitors approved for market or in late-stage development globally. The oral small-molecule profile of ICP-054 has the potential to offer advantages in dosing convenience, patient adherence, and clinical accessibility over currently approved biologic IL-17 therapies.\nNotably, in October 2025, the company's wholly-owned subsidiary, Innocare Pharma Inc., entered into a licensing agreement with Zenas BioPharma, Inc. Under this agreement, Innocare granted Zenas the exclusive rights to develop, manufacture, and commercialize the oral IL-17AA/AF inhibitor ICP-054 (ZB021) in all regions outside of Greater China and Southeast Asia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186054640","isCrawlerRequest":true}